乙型肝炎病毒（Hepatitis B virus，HBV）感染是一个重大的全球公共卫生问题，2019年全球约有2.96亿人感染了慢性HBV，其中有82万人死于HBV相关并发症，如肝硬化和肝癌。世界卫生组织（World Health ...

诸多研究表明，HBV疫苗接种后有较高的免疫应答效果，且安全性也得到证实，虽然我国在HBV的防治和乙肝的诊断与治疗方面取得了显著进展。但现有研究表明我国乙肝疫苗接种率依旧较低，仅约10%－20%，探究影响我国居民乙肝疫苗接种意愿的因素依然十分重要，对人 ...

SCG has revealed late-breaking data outcomes from the Phase I clinical trial of autologous hepatitis B virus (HBV)-specific T ...

Screening rates for hepatitis D virus are not ideal among individuals with hepatitis B virus, who also have a higher all-cause mortality rate.

The potency of GIGA-2339 is claimed to be more than 2,000 times greater than that of plasma-derived HBV treatments.

编者按当前，关于妊娠期间采用抗病毒药物以预防乙型肝炎病毒（HBV）母婴传播的最佳治疗时机，尚未形成统一意见。传染病专家、产科医生以及国内外不同地区均提出了各异的建议。因此，关于在孕24-28周或28-32周启动抗病毒药物治疗以阻断母婴传播的效果，及其 ...

The following is a summary of “Cytokine and chemokine profiling in chronic hepatitis- C and -B virus infections with high viral load.” published in the August 2024 issue of Allergy and Immunology by ...

Analyst Michael Ulz from Morgan Stanley maintained a Hold rating on Vir Biotechnology (VIR – Research Report) and keeping the price target at ...

Regional Office for Africa has established a Regional Validation Committee to oversee the elimination of mother-to-child ...

SCG Cell Therapy Pte Ltd (SCG), a clinical-stage biotechnology company focused on developing innovative immunotherapies for infectious diseases and associated cancers, announced late-breaking data ...

Epigenic Therapeutics, a leading biotechnology company dedicated to developing next-generation gene modulation therapy, today announced that it has received approval of clinical trial application (CTA ...

An estimated 1.4 million Americans are affected by Hepatitis B Virus, which can cause serious liver disease and eventually ...